A Phase II Multicenter, Randomized, Double-blind, Placebo-Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subject with Moderate to Severe Active Systemic Lupus Erythematosus
A study for patients with Systemic Lupus Erythematosus using study drug ALX-0061
Sponsor: Ablynx
Enrolling: Male and Female Patients
Study Length: 1 Years
IRB Number: AAAP7757
U.S. Govt. ID: NCT02437890
Contact: Anca Askanase: 212-305-0856 / ada20@cumc.columbia.edu
Additional Study Information: The goal of this study is to test a new lupus drug. This drug interrupts the function of a chemical in the body called IL-6, and IL-6 may be overactive in people with lupus. ALX-0061 is a study drug that will be administered subcutaneously to subjects with moderate to severe active, seropositive Systemic Lupus Erythematosus (SLE) compared to placebo.
This study is closed
Anca Askanase, MD, MPH
Do You Qualify?
Do you have a diagnosis of Systemic Lupus Erythematosus Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Anca Askanase